Kymera Therapeutics Inc’s filing revealed that its Director Esposito Pamela unloaded Company’s shares for reported $0.37 million on Jan 20 ’26. In the deal valued at $67.91 per share,5,500 shares were sold. As a result of this transaction, Esposito Pamela now holds 0 shares worth roughly $0.0.
Then, PAMELA ESPOSITO bought 5,500 shares, generating $382,470 in total proceeds.
Before that, Mainolfi Nello sold 30,000 shares. Kymera Therapeutics Inc shares valued at $2,341,939 were divested by the Chief Executive Officer at a price of $78.06 per share. As a result of the transaction, Mainolfi Nello now holds 663,077 shares, worth roughly $46.37 million.
Wolfe Research downgraded its Kymera Therapeutics Inc [KYMR] rating to a Peer perform from a an Outperform in a research note published recently. B. Riley Securities also remained covering KYMR and reiterated its “Buy” recommendation on October 24, 2025. Mizuho started covering the stock on October 21, 2025. It rated KYMR as “an Outperform”.
Price Performance Review of KYMR
On Friday, Kymera Therapeutics Inc [NASDAQ:KYMR] saw its stock fall -3.90% to $69.93. Over the last five days, the stock has lost -1.67%. Kymera Therapeutics Inc shares have risen nearly 58.46% since the year began. Nevertheless, the stocks have fallen -10.13% over the past one year.
How much short interest is there in Kymera Therapeutics Inc?
A steep rise in short interest was recorded in Kymera Therapeutics Inc stocks on 2025-12-31, dropping by -0.75 million shares to a total of 7.94 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 8.69 million shares. There was a decline of -9.42%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 18, 2025 when H.C. Wainwright resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $70.
